Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-701 and Keytruda in relapsed or refractory bladder cancer
NCT02925533Phase 1Terminated
- Start
- Dec 2016
- Primary completion
- Jun 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of vofatamab in bladder cancer. Primary endpoint: Safety of B-701 in combination with Pembrolizumab at 2 years. Started Dec 2016; status: terminated.
02
Drugs
vofatamab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT02925533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02925533.